AOA Dx

At AOA Dx, we are at the forefront of developing the next generation of biomarkers for early cancer detection. As our team dives deeper into glycolipids, we are increasingly recognizing their potential may extend far beyond diagnostic use. A recent study, led by Prof. H. Uri Saragovi and collaborators from McGill University, revealed that specific glycolipids found in blood could be key indicators of a patient's cancer journey and the patient’s long term outcomes. This discovery highlights a crucial insight: like other impactful cancer biomarkers in history, glycolipids may offer more than just detection. They could play a role in prognosis and targeted therapy. This research opens exciting possibilities for glycolipids as versatile biomarkers, potentially reshaping how we approach the field of cancer and most importantly patient care. Read Prof. Saragovi’s work here: https://lnkd.in/dvEAMGhH

As part of our Symptomatic campaign, we are amplifying the voices of women whose symptoms were dismissed or misdiagnosed, shedding light on the critical need for better awareness and understanding. Sbba Siddique’s ovarian cancer diagnosis was delayed after her symptoms were misattributed to menopause or irritable bowel syndrome (IBS). She has spoken out about the medical gaslighting she experienced during this time. Her story highlights the urgent need for early detection tools to empower women with timely, accurate information to make informed decisions about their health.

“While some progress has been made in improving what we know about the health of women and girls, so much more remains to be understood,” said Sheila Burke, co-chair of the study committee and senior policy advisor at Baker Donelson. "This report lays out a bold and transformative vision for women’s health,” said Victor Dzau president of the National Academy of Medicine. “To advance the health of the entire nation, it is imperative that federal support for women’s health research is not only bolstered now, but upheld in the years to come.”

We’re just over a month away from #JPM2025! 🎉 If you're curious about how we’re revolutionizing the field of lipidomics by leveraging tumor marker gangliosides, the next frontier in early cancer detection, connect with Oriana Papin-Zoghbi or Abigail McElhinny to find a time to meet. 👏

Flashback Friday! Check out our team at the International Society of Liquid Biopsy conference the other week. Here is one of our key takeaways from the conference! 📣 Multi-omics is the future: Standard protein markers alone aren’t enough. Multi-omic approaches are essential for early detection and monitoring. AOA is currently focused on a multi-omic approach for detecting ovarian cancer earlier, and we are excited to be able to participate in industry discussions on this topic. Abigail McElhinny Moises Zapata Rachel C. Mattie Goldberg Enkhtuya Radnaa

We are proud to have advisors like Dr. Elizabeth Garner on our team to help us make early detection a reality for ovarian cancer patients.

The other week, we presented our latest research at the International Society of Liquid Biopsy conference. The presented study investigates the potential of TMGs as biomarkers for the early detection of ovarian cancer. Using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), researchers analyzed serum samples from 70 non-cancer subjects and 35 ovarian cancer patients (including 8 early-stage and 27 late-stage cases). The analysis identified 31 distinct TMG species, including GD1, GD2, and GD3 gangliosides. Check out the full press release here: https://lnkd.in/dBSwJ_ME

Did you know? Investment in research on women’s health conditions (outside of cancer) is 10X less than in men’s health conditions. Don't miss our CEO + Co-Founder Oriana Papin-Zoghbi on the Women's Health Access Matters panel next week! 📅 Date: Tuesday, December 3, 2024 ⏰ Time: 1:00-2:00 pm ET 🔗 Register now: https://lnkd.in/gXGn52XV Join a dynamic discussion that highlights actionable strategies to fast-track innovation, drive investment, and unlock substantial economic and societal benefits. CC: Carolee Lee, Lori Frank, Jessica J. Federer, Alice Zheng, Foreground Capital, Alexandra Lundin, Insight Partners

Don't miss Rachel C.'s presentation tomorrow, Saturday November 23rd at 11:00-12:30pm at the International Society of Liquid Biopsy! Location: PP01.75, Exhibit Hall (Adams C-D) -->https://lnkd.in/dBSwJ_ME We look forward to learning more about the latest advancements in this space and presenting our work! If you'd like to find a time to meet, link up with Abigail McElhinny, Vuna Fa, Mattie Goldberg, Brendan Giles, Moises Zapata or Enkhtuya Radnaa. See you there!

TBT! Our co-founder and CRO Anna Milik Jeter spoke at the Utah Life Science Summit and was part of a fire-side chat with Liz Powell, President+ Founder of G2G - Innovative Government Affairs Consulting and Angela Dotson, CEO of Empress Medical 👏